ASPG and hypersensitivity: A recent study in The Netherlands on the cost-effectiveness of switching to Erwinia asparaginase versus discontinuing asparaginase following a hypersensitivity reaction to pegaspargase evaluated cost per life years saved using a wider perspective, including hospital costs, burden of switching and patient experience of the hypersensitivity reactions [51].